Literature DB >> 11239469

Lack of proteasome active site allostery as revealed by subunit-specific inhibitors.

J Myung1, K B Kim, K Lindsten, N P Dantuma, C M Crews.   

Abstract

The chymotrypsin-like (CT-L) activity of the proteasome is downregulated by substrates of the peptidyl-glutamyl peptide hydrolyzing (PGPH) activity. To investigate the nature of such interactions, we synthesized selective alpha',beta'-epoxyketone inhibitors of the PGPH activity. In cellular proliferation and protein degradation assays, these inhibitors revealed that selective PGPH inhibition was insufficient to inhibit protein degradation, indicating that the CT-L and PGPH sites function independently. We also demonstrated that CT-L inhibition by a PGPH substrate does not require the occupancy of the PGPH site or hydrolysis of the PGPH substrate. Thus, these results support a model in which a substrate of one subunit regulates the activity of another via binding to a noncatalytic site(s) rather than through binding to an active site.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239469     DOI: 10.1016/s1097-2765(01)00188-5

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  39 in total

Review 1.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

2.  Academic-Industrial Collaboration: Toward the Consilience of Two Solitudes.

Authors:  Stephen Hanessian
Journal:  ACS Med Chem Lett       Date:  2015-12-22       Impact factor: 4.345

Review 3.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

4.  Lysine 188 substitutions convert the pattern of proteasome activation by REGgamma to that of REGs alpha and beta.

Authors:  J Li; X Gao; J Ortega; T Nazif; L Joss; M Bogyo; A C Steven; M Rechsteiner
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

5.  Proteasome inhibition by fellutamide B induces nerve growth factor synthesis.

Authors:  John Hines; Michael Groll; Margaret Fahnestock; Craig M Crews
Journal:  Chem Biol       Date:  2008-05

6.  Major Histocompatibility Complex (MHC) Class I Processing of the NY-ESO-1 Antigen Is Regulated by Rpn10 and Rpn13 Proteins and Immunoproteasomes following Non-lysine Ubiquitination.

Authors:  Richard Golnik; Andrea Lehmann; Peter-Michael Kloetzel; Frédéric Ebstein
Journal:  J Biol Chem       Date:  2016-02-22       Impact factor: 5.157

7.  Monitoring of ubiquitin-proteasome activity in living cells using a Degron (dgn)-destabilized green fluorescent protein (GFP)-based reporter protein.

Authors:  Ruth Greussing; Hermann Unterluggauer; Rafal Koziel; Andrea B Maier; Pidder Jansen-Dürr
Journal:  J Vis Exp       Date:  2012-11-10       Impact factor: 1.355

8.  Proteasome allostery as a population shift between interchanging conformers.

Authors:  Amy M Ruschak; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

9.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

10.  Role of the proteasome in excitotoxicity-induced cleavage of glutamic acid decarboxylase in cultured hippocampal neurons.

Authors:  Márcio S Baptista; Carlos V Melo; Mário Armelão; Dennis Herrmann; Diogo O Pimentel; Graciano Leal; Margarida V Caldeira; Ben A Bahr; Mário Bengtson; Ramiro D Almeida; Carlos B Duarte
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.